Prevalence of HLA-B*57:01 allele in HIV-positive and HIV-negative population of eastern India: An epidemiological study
Introduction: The nucleoside analogue reverse-transcriptase inhibitor Abacavir has potent antiviral activity against HIV; however, 5–8% patients develop hypersensitivity reactions within six weeks of treatment. The presence of the HLA-B*57:01 allele is strongly associated with the risk of Abacavir-a...
Main Authors: | Abhilasha Gautam, Jaya Chakravarty, Ankita Chourasia, Saurabh Sharma, Tanmoy Sarkar, Parimal Das |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-11-01
|
Series: | Clinical Epidemiology and Global Health |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S221339842200224X |
Similar Items
-
HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
by: Catherine Butkus Small, et al.
Published: (2017-04-01) -
HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study
by: Karam Mounzer, et al.
Published: (2019-01-01) -
Human leukocyte antigen HLA-B*57:01 status in HIV-1 patients developing hypersensitivity reactions in Benin: a pilot study
by: Adefounke Prudencia Adechina, et al.
Published: (2024-07-01) -
Severe abacavir hypersensitivity reaction in a patient with human immunodeficiency virus infection: a case report
by: Mathew K. Koech, et al.
Published: (2022-11-01) -
Adverse drug reactions triggered by the common HLA-B*57:01 variant: virtual screening of DrugBank using 3D molecular docking
by: George Van Den Driessche, et al.
Published: (2018-01-01)